Basic Information 【 display / non-display




Graduate School of Medicine , Doctorial Course in Medicine , Oncoregulatory Medicine



Date of Birth


Postal address

Dept. Hematology, Akita Univ.

Research Fields, keywords


Mail Address

E-mail address

Telephone number


FAX number


Academic Background (Undergraduate Level) 【 display / non-display

  • Akita University   Faculty of Medicine   1990.03  Graduated

Academic Background (Graduate Level) 【 display / non-display

  • Akita University  Graduate School,Division of Medicine  Doctor's Degree Program  1997.03  Completed

History of going abroad to study 【 display / non-display

  • 2003.05

    Saskatoon Cancer Centre, University of Saskatchewan   Postdoctoral Research Fellowship

Professional Career On-Campus 【 display / non-display

  • 2015.02

    Akita University   Graduate School of Medicine   Doctorial Course in Medicine   Oncoregulatory Medicine   Professor

  • 2006.04

    Akita University   School of Medicine   School of Medicine   Lecturer


Articles 【 display / non-display

  • Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate.

    Takahashi N, Kameoka Y, Tagawa H, et al.

    Int J Hematol.   2010.01

  • Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.

    Takahashi N, Wakita H, Miura M, Scott SA, et al

    Clin Pharmacol Ther.   2010.01

  • Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.

    Takahashi N, Miura M, Scott SA, et al

    J Hum Genet.   2010.01

  • Clinical significance of a single nucleotide polymorphism and&0d0a;allelic imbalance of matrix metalloproteinase-1&0d0a;promoter region in prostate cancer

    Tsuchiya N, Narita S, Kumazawa S, Inoue T, Ma Z, Tsuruta H, Saito M, Horikawa Y, Yuasa T, Satoh S, Ogawa O, Habuchi T

    Oncology Rreports   22 ( 3 )   493 - 499   2009.01

  • Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia.

    Yamanaka Y, Tagawa H, Takahashi N, et al.

    Blood   2009.01

display all >>